EpilepsyPhase 2NCT00965575
Pilot Study of Melatonin and Epilepsy
A Phase 2 study testing Melatonin in people with Epilepsy, run by Children's Hospital Medical Center, Cincinnati at 1 site in United States.
Trial summary
The prevalence of epilepsy is 1% in the USA. About 30% of epilepsy patients eventually become refractory to medical treatment. Co morbid conditions are becoming as important as seizure control as these affect overall wellbeing. Read more about this study
- Who is it for?
- Ages 6 to 11 years
- Conditions the study is for
- Epilepsy
- What is being tested?
- Melatonin
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 11 participants
- Where
- 1 siteUnited States
- Study dates
- Jun 2011to Aug 2014
- Phase
- Phase 2
- Are there results?
- Yes, posted in the registrySummary in the doctors' view
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 6 to 11 years
- All sexes
- No healthy volunteers
- Child
Who may be able to join
- Age 6-11 years (prepubertal based on tanner staging)
- Patients with epilepsy (diagnosis based on ILAE).
- Normal intelligence based on school placement (defined as age appropriate; an IEP due to epilepsy related causes is acceptable as is placement in a higher grade) or IQ>70 (testing done with in 12 months of enrollment)
- No history of significant snoring- loud snoring every night outside of a room with closed door
- Combined score of 30 or more on sleep fragmentation, parasomnia and daytime drowsiness subscales on SBQ.
Who cannot join
- History of significant snoring- loud snoring every night heard outside of a room with closed door
- Diagnosis of obstructive sleep apnea (OSA) or periodic limb movement disorder on PSG
- Vagus nerve stimulator implanted
- History of a major psychiatric disease (e.g. psychosis, major depression)
- History of autism or pervasive development disorder
- Severe neuro-developmental disabilities, as determined by PI
Show all 13Show fewer
- Clinically significant systemic organic disease, as determined by PI
- Current use of melatonin or sustained release melatonin
- Prior use of sustained release melatonin
- Current use of any hypnotic medications except for medications used as a rescue treatment for seizures
- Use of psychoactive or stimulant medication for attention deficit disorders
- Subjects with immune disorders, lympho-proliferative disorders, and those taking oral corticosteroids or other immuno-suppressants
- Subject or parent/legal guardian might not be reasonably expected to be compliant with or to complete the study.
Trial locations and contacts
1 site in 1 country.
United States1 site
Cincinnati Children's Hospital Medical Center
Cincinnati, Ohio, 45229
About this study
Official title: Melatonin and Sleep in Patients With Epilepsy
The prevalence of epilepsy is 1% in the USA. About 30% of epilepsy patients eventually become refractory to medical treatment. Co morbid conditions are becoming as important as seizure control as these affect overall wellbeing. Sleep related complaints are frequent in them including, frequent arousals, difficulty falling asleep and excessive daytime sleepiness. Polysomnography shows increased arousal index, sleep onset latency, and stage shifts and fragmented REM sleep. Poor sleep efficiency causes daytime fatigue, poor cognition and behavior and can worsen seizure control. Stabilizing sleep may improve seizure control. Melatonin is a naturally occurring hormone in the body involved in the regulation of circadian rhythm and exogenously given, has been shown to decrease sleep onset latency, arousals, and there-by increase sleep efficiency in healthy pediatric patients. Similar data does not exist in the patients with epilepsy. As sleep has important impact on epilepsy and overall functioning, it is important to study effect of melatonin in children with epilepsy.
We propose a randomized double blind placebo controlled trial with a cross-over design. Our hypothesis is that, for patients with epilepsy, administration of melatonin 30 minutes before bedtime for four weeks may:
- Improve the quality of sleep;
- Improve daytime functioning in terms of cognition, behavior and quality of life;
- Decrease epileptic potential. We will use polysomnography, electroencephalogram, psychomotor vigilance task, seizure diary, and questionnaires to assess the effect of melatonin on these domains. This study may help to improve the care of children with epilepsy.
Read the detailed description
Hypothesis 1: Melatonin treatment improves the quality of sleep in patients with epilepsy.
Various studies evaluating sleep problems in patients with epilepsy using questionnaires have shown that 34-45% patients have sleep related problems [1-3]. Cortesi et al reported that children with seizures had higher sleep difficulties than their siblings and controls[4]. Bedtime difficulties, sleep fragmentation, daytime sleepiness, snoring and parasomnia were reported as sleep problems in this population [2, 4]. Patients with refractory seizures and using multiple antiepileptic drugs(AED) showed worse problems[5]. On polysomnography (PSG) these patients show increased arousal index, increased sleep onset latency, fragmented or reduced REM sleep, increased stage shifts and increased Stage 1 sleep and decreased stage 2 and slow wave sleep. [6-9] Melatonin has been shown to decrease sleep onset latency and increase total sleep time and subjectively improve sleep in healthy individuals.[10-15]. Various studies using fast release and sustained release formulations have suggested improvement in sleep efficiency and decreased arousals as well.[16-18] In a randomized placebo controlled study by Gupta et al[19], Melatonin was shown to subjectively improve sleep in patients with epilepsy. Studies in children with neurodevelopmental delay and autism along with epilepsy have also reported similar findings.[17, 20-23] Rationale: There are significant sleep disturbances in children with epilepsy. Melatonin has been shown to improve sleep in this group of patients. However, all these studies report improvement based on parent report and only one study is placebo-controlled. Our study will assess this in randomized placebo controlled fashion and will provide both subjective and objective improvement in sleep with the primary outcome being improved sleep efficiency on PSG.
Hypothesis 2: Melatonin improves daytime functioning in terms of cognition, behavior and quality of life in the patients with epilepsy.
Poor sleep and epilepsy both have detrimental effect on cognition.[24-27] Melatonin by improving sleep may improve cognitive functioning in these patients.
Some patients with epilepsy have poor behavior and psychiatric function.[28-30] Severity of these problems are related to the worsening of the sleep problems.[2, 4] Melatonin by improving sleep may improve the behavior in these patients.
Epilepsy has negative effect on various aspects of the patients' life including social, behavioral, and academic [31, 32]. Questionnaires have been developed to assess the impact on overall quality of life of the patients [33, 34]. These tools are helpful to quickly and subjectively assess quality of life. Based on these studies, it has been shown that patients with refractory seizures have poor quality of life [33-37] and an improvement is seen if the seizure frequency is decreased.[38-41] There has been only one study reporting quality of life (QOL) after use of melatonin in patients with epilepsy. In this randomized placebo controlled study, significant improvement was seen in the cognitive, anxiety and behavior subscales of the QOLCE after use of melatonin.[42] To date, there are no studies reporting on the effect of melatonin on cognition or behavior in epilepsy patients.
Rationale: Poor behavior, cognition and quality of life have been reported in children with epilepsy and sleep disturbances. By improving the quality of sleep, melatonin will improve all these domains. QOLCE has been validated and used in epilepsy patients and will assess the QOL in these patients. Vigilance is the component of cognition that is most consistently and drastically affected by sleep deprivation. PVT measures "vigilant attention" and has been used widely in adult patients to assess the effect of sleep deprivation on cognition. It has been described as a very sensitive measure to see both acute and chronic effects of sleep deprivation. BASC-PRS has been used to assess behavior in children and is found equally useful in epilepsy patients as child behavior check list (CBCL). It is a sensitive tool to compare changes over shorter time span.
Hypothesis 3: Melatonin treatment decreases epileptic potential. Sleep deprivation has been known to induce seizures and epileptic discharges on EEG[43]. Seizures are also known to occur with change in the depth or rhythmicity of sleep.[43] Patients with epilepsy report sleep deprivation as a significant seizure precipitating factor [44, 45]. In a recent study, Haut et al reported that one hour of additional sleep on the preceding night decreased relative odds of a seizure on the subsequent day to 0.91[46]. In a study Oliveira reported that treatment of obstructive sleep apnea (OSA) decreased interictal epileptiform discharges.[47] The belief that fewer epileptiform discharges represent better seizure control is controversial. But a study suggested that decreasing epileptiform discharges on EEG improves behavior.[48] Studies investigating obstructive sleep apnea in patients with epilepsy have reported improvement in seizure control with treatment of OSA [49-54]. These suggest that stabilizing sleep has a beneficial effect on seizure control.
Many studies that evaluated melatonin in epilepsy patients report overall improvement in seizure control[17, 21], while others report no worsening of seizure control after the use of melatonin[20, 22, 23]. Coppola et al reported inconclusive results with regards to seizure control after melatonin use[55]. However, these studies are not powered to account for variability in seizure occurrence reported with epilepsy patients.
Rationale: There are no randomized controlled studies available to evaluate the effect of melatonin on seizure control in the children with epilepsy. This study will identify the effect of short term use of melatonin compared with placebo and will provide pilot data to evaluate this effect in a larger trial in future.
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
MelatoninDrug
Also called natural supplement
Sustained release formula (Brand: Jigsaw); dosage will be 9mg for all subjects. Taken 30 minutes prior to bedtime for four weeks.
PlacebosDrug
Also called Placebo
Placebo. Taken 30 minutes prior to bedtime for four weeks.
| Study group | Role | What they receive |
|---|---|---|
| Melatonin | Experimental | Subjects will take sustained release melatonin 30 minutes prior to bedtime for four weeks Receives: Drug: Melatonin |
| Placebos | Placebo comparator | Subjects will take a placebo 30 minutes before bedtime for four weeks Receives: Drug: Placebos |
What is being measured
The primary outcome is the main question the study is designed to answer.
Sleep Latency Wakefulness After Sleep Onset (WASO)
Sleep Latency Wakefulness After Sleep Onset (WASO). Calculated as the sum of wake time minutes from sleep onset to the final awakening.
Measured: 13 weeks
Secondary outcomes (1)
Seizure Frequency
Seizure frequency was determined by parent/caregiver report on a seizure diary which was filled out after each seizure which is an accepted patient-reported outcome measure. Data is given as number of seizures per month.
Measured: 13 weeks
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted25 Aug 2009 (estimated)
- Study startJun 2011
- Primary completionJun 2014
- Study completionAug 2014
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Other trials for EpilepsyStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 2
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- Triple blind
- Who is masked
- Participant, Care provider, Investigator
- Enrolment
- 11 participants (actual)
Sponsor and investigators
- Lead sponsor
- Children's Hospital Medical Center, Cincinnati
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Sejal Jain, MD, Principal investigator, Children's Hospital Medical Center, Cincinnati
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT00965575
- Sponsor's protocol ID
- 2009-1042
- Status last verified
- Feb 2017
- First submitted
- 24 Aug 2009
- Last updated
- 1 Oct 2020
- Results posted
- Yes, on ClinicalTrials.gov
- Data monitoring committee
- Yes
- Individual data sharing
- No: There is no plan to share data at this time.
Study at a glance
From the registry record, last updated by the sponsor on 1 Oct 2020. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Melatonin and Sleep in Patients With Epilepsy
- ClinicalTrials.gov ID
- NCT00965575
- Acronym / sponsor ID
- 2009-1042
- Conditions
- Epilepsy
- Keywords
- epilepsy, sleep, seizures, cognition
- Phase
- Phase 2
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 11 participants (actual)
- Lead sponsor
- Children's Hospital Medical Center, CincinnatiUniversity, hospital or other
- Study start
- Jun 2011
- Primary completion
- Jun 2014 (actual)
- Study completion
- Aug 2014 (actual)
- First posted
- 25 Aug 2009 (estimated)
- Results
- Posted 1 Oct 2020
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The prevalence of epilepsy is 1% in the USA. About 30% of epilepsy patients eventually become refractory to medical treatment. Co morbid conditions are becoming as important as seizure control as these affect overall wellbeing. Sleep related complaints are frequent in them including, frequent arousals, difficulty falling asleep and excessive daytime sleepiness. Polysomnography shows increased arousal index, sleep onset latency, and stage shifts and fragmented REM sleep. Poor sleep efficiency causes daytime fatigue, poor cognition and behavior and can worsen seizure control. Stabilizing sleep may improve seizure control. Melatonin is a naturally occurring hormone in the body involved in the regulation of circadian rhythm and exogenously given, has been shown to decrease sleep onset latency, arousals, and there-by increase sleep efficiency in healthy pediatric patients. Similar data does not exist in the patients with epilepsy. As sleep has important impact on epilepsy and overall functioning, it is important to study effect of melatonin in children with epilepsy.
We propose a randomized double blind placebo controlled trial with a cross-over design. Our hypothesis is that, for patients with epilepsy, administration of melatonin 30 minutes before bedtime for four weeks may:
- Improve the quality of sleep;
- Improve daytime functioning in terms of cognition, behavior and quality of life;
- Decrease epileptic potential. We will use polysomnography, electroencephalogram, psychomotor vigilance task, seizure diary, and questionnaires to assess the effect of melatonin on these domains. This study may help to improve the care of children with epilepsy.
Detailed description
Hypothesis 1: Melatonin treatment improves the quality of sleep in patients with epilepsy.
Various studies evaluating sleep problems in patients with epilepsy using questionnaires have shown that 34-45% patients have sleep related problems [1-3]. Cortesi et al reported that children with seizures had higher sleep difficulties than their siblings and controls[4]. Bedtime difficulties, sleep fragmentation, daytime sleepiness, snoring and parasomnia were reported as sleep problems in this population [2, 4]. Patients with refractory seizures and using multiple antiepileptic drugs(AED) showed worse problems[5]. On polysomnography (PSG) these patients show increased arousal index, increased sleep onset latency, fragmented or reduced REM sleep, increased stage shifts and increased Stage 1 sleep and decreased stage 2 and slow wave sleep. [6-9] Melatonin has been shown to decrease sleep onset latency and increase total sleep time and subjectively improve sleep in healthy individuals.[10-15]. Various studies using fast release and sustained release formulations have suggested improvement in sleep efficiency and decreased arousals as well.[16-18] In a randomized placebo controlled study by Gupta et al[19], Melatonin was shown to subjectively improve sleep in patients with epilepsy. Studies in children with neurodevelopmental delay and autism along with epilepsy have also reported similar findings.[17, 20-23] Rationale: There are significant sleep disturbances in children with epilepsy. Melatonin has been shown to improve sleep in this group of patients. However, all these studies report improvement based on parent report and only one study is placebo-controlled. Our study will assess this in randomized placebo controlled fashion and will provide both subjective and objective improvement in sleep with the primary outcome being improved sleep efficiency on PSG.
Hypothesis 2: Melatonin improves daytime functioning in terms of cognition, behavior and quality of life in the patients with epilepsy.
Poor sleep and epilepsy both have detrimental effect on cognition.[24-27] Melatonin by improving sleep may improve cognitive functioning in these patients.
Some patients with epilepsy have poor behavior and psychiatric function.[28-30] Severity of these problems are related to the worsening of the sleep problems.[2, 4] Melatonin by improving sleep may improve the behavior in these patients.
Epilepsy has negative effect on various aspects of the patients' life including social, behavioral, and academic [31, 32]. Questionnaires have been developed to assess the impact on overall quality of life of the patients [33, 34]. These tools are helpful to quickly and subjectively assess quality of life. Based on these studies, it has been shown that patients with refractory seizures have poor quality of life [33-37] and an improvement is seen if the seizure frequency is decreased.[38-41] There has been only one study reporting quality of life (QOL) after use of melatonin in patients with epilepsy. In this randomized placebo controlled study, significant improvement was seen in the cognitive, anxiety and behavior subscales of the QOLCE after use of melatonin.[42] To date, there are no studies reporting on the effect of melatonin on cognition or behavior in epilepsy patients.
Rationale: Poor behavior, cognition and quality of life have been reported in children with epilepsy and sleep disturbances. By improving the quality of sleep, melatonin will improve all these domains. QOLCE has been validated and used in epilepsy patients and will assess the QOL in these patients. Vigilance is the component of cognition that is most consistently and drastically affected by sleep deprivation. PVT measures "vigilant attention" and has been used widely in adult patients to assess the effect of sleep deprivation on cognition. It has been described as a very sensitive measure to see both acute and chronic effects of sleep deprivation. BASC-PRS has been used to assess behavior in children and is found equally useful in epilepsy patients as child behavior check list (CBCL). It is a sensitive tool to compare changes over shorter time span.
Hypothesis 3: Melatonin treatment decreases epileptic potential. Sleep deprivation has been known to induce seizures and epileptic discharges on EEG[43]. Seizures are also known to occur with change in the depth or rhythmicity of sleep.[43] Patients with epilepsy report sleep deprivation as a significant seizure precipitating factor [44, 45]. In a recent study, Haut et al reported that one hour of additional sleep on the preceding night decreased relative odds of a seizure on the subsequent day to 0.91[46]. In a study Oliveira reported that treatment of obstructive sleep apnea (OSA) decreased interictal epileptiform discharges.[47] The belief that fewer epileptiform discharges represent better seizure control is controversial. But a study suggested that decreasing epileptiform discharges on EEG improves behavior.[48] Studies investigating obstructive sleep apnea in patients with epilepsy have reported improvement in seizure control with treatment of OSA [49-54]. These suggest that stabilizing sleep has a beneficial effect on seizure control.
Many studies that evaluated melatonin in epilepsy patients report overall improvement in seizure control[17, 21], while others report no worsening of seizure control after the use of melatonin[20, 22, 23]. Coppola et al reported inconclusive results with regards to seizure control after melatonin use[55]. However, these studies are not powered to account for variability in seizure occurrence reported with epilepsy patients.
Rationale: There are no randomized controlled studies available to evaluate the effect of melatonin on seizure control in the children with epilepsy. This study will identify the effect of short term use of melatonin compared with placebo and will provide pilot data to evaluate this effect in a larger trial in future.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- Triple blind (participant, care provider, investigator)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Melatonin | Experimental | Drug: MelatoninSubjects will take sustained release melatonin 30 minutes prior to bedtime for four weeks |
| Placebos | Placebo comparator | Drug: PlacebosSubjects will take a placebo 30 minutes before bedtime for four weeks |
Who may qualify
- Ages
- 6 to 11 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child
Key inclusion criteria (5 listed)
- Age 6-11 years (prepubertal based on tanner staging)
- Patients with epilepsy (diagnosis based on ILAE).
- Normal intelligence based on school placement (defined as age appropriate; an IEP due to epilepsy related causes is acceptable as is placement in a higher grade) or IQ>70 (testing done with in 12 months of enrollment)
- No history of significant snoring- loud snoring every night outside of a room with closed door
- Combined score of 30 or more on sleep fragmentation, parasomnia and daytime drowsiness subscales on SBQ.
Key exclusion criteria (13 listed)
- History of significant snoring- loud snoring every night heard outside of a room with closed door
- Diagnosis of obstructive sleep apnea (OSA) or periodic limb movement disorder on PSG
- Vagus nerve stimulator implanted
- History of a major psychiatric disease (e.g. psychosis, major depression)
- History of autism or pervasive development disorder
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| MelatoninAlso: natural supplementSustained release formula (Brand: Jigsaw); dosage will be 9mg for all subjects. Taken 30 minutes prior to bedtime for four weeks. | Drug | Melatonin |
| PlacebosAlso: PlaceboPlacebo. Taken 30 minutes prior to bedtime for four weeks. | Drug | Placebos |
Primary outcome
Sleep Latency Wakefulness After Sleep Onset (WASO)
Time frame: 13 weeks
Sleep Latency Wakefulness After Sleep Onset (WASO). Calculated as the sum of wake time minutes from sleep onset to the final awakening.
1 secondary outcome
Seizure Frequency
Time frame: 13 weeks
Results and safety
Loading the posted results from ClinicalTrials.gov…
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 1 Oct 2020.
- Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
- Sleep MedicineLink provided by the sponsor.
- Individual participant dataSharing planned: No. There is no plan to share data at this time.
Related trials for Epilepsy
Enrolling by invitation
An Examination of Cognitive and Sensorimotor Processes in Patients With Epilepsy
Epilepsy
RecruitingObservational study
Surgery as a Treatment for Medically Intractable Epilepsy
Epilepsy, Epilepsy, Temporal Lobe
RecruitingObservational study
Tumor Related Epilepsy
Epilepsy, Cancer
RecruitingObservational study
Investigating Epilepsy: Screening and Evaluation
Seizures, Epilepsy
Recruiting
Optimizing Brain Stimulation Parameters
Epilepsy; Seizure
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Sejal Jain, MD principal investigator
Children's Hospital Medical Center, Cincinnati
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 2 study testing Melatonin in people with Epilepsy, run by Children's Hospital Medical Center, Cincinnati at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 13 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 1 Oct 2020. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
Yes. Results are posted in the registry (first posted 1 Oct 2020). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Sleep Latency Wakefulness After Sleep Onset (WASO) (time frame: 13 weeks). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 1 Oct 2020; AzTrials last refreshed its copy on 26 Oct 2026.